Newswise — MADISON, Wisconsin, Feb. 23, 2016 – The Americas Committee for Treatment and Research in Multiple (ACTRIMS) closed its inaugural ACTRIMS Forum 2016 Saturday by recognizing the research contributions of three young investigators.

Nathaniel Lizak of Monash University, Melbourne, Australia, who presented research results showing immunomodulatory therapy slows accumulation of disability in moderately advanced multiple sclerosis, was recognized as the Best Young Investigator for an oral presentation.

Two young investigators were recognized for best poster presentations. They are:• Jennifer Orthmann-Murphy, Johns Hopkins School of Medicine, for her research on in vivo imaging of cortical demyelination and remyelination, and • Matthew Schindler, National Institutes of Health, for his research on cytotoxic T-lymphocyte antigen-4 haploinsufficiency-associated neuroinflammation – clinical and radiographic features.

Opportunities for young investigators to present their findings and consult with established researchers and clinicians were among the primary goals of ACTRIMS Forum 2016. The event drew more than 600 participants to New Orleans.

The theme for the forum, Progressive MS: From Bench to Bedside and Back, was reflected in the presentations about ongoing clinical trials of neuroprotective, neuroregenerative and immunomodulatory agents in progressive MS, advances in the development of serological and imaging markers of MS disease progression, and cutting-edge discoveries in the pathogenesis and management of progressive MS from world-renowned experts in the field.

All of the abstracts are available in the online program section of the ACTRIMS 2016 website, ACTRIMS 2017 will be held in Orlando, Florida, Feb. 23 – 25, 2017.

About ACTRIMSThe Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) provides leadership in the field of multiple sclerosis and other demyelinating diseases. ACTRIMS® is a community of leaders dedicated to the treatment of and research in multiple sclerosis, dissemination of knowledge and education and collaboration among disciplines. Founded in 1995, it serves as the U.S. and Canadian counterpart to ECTRIMS, the European Committee on Treatment and Research in Multiple Sclerosis.